MuReva is developing a medical device to eliminate mouth ulcers, the most common, debilitating and costly side effect of cancer therapy.
Benefits to Physicians
Reduce Treatment Interruptions, Risk of Infection, and Opioid Usage
Benefits to Patients
Reduce Pain, Increase Quality of Life, Maintain Ability to Swallow and Salivary Flow
Reduce Patient Costs, Inpatient Admissions and Increase Patient Satisfaction
Reduce Overall Cost of Care, Improve Patient Outcomes and Increase Compliance to Treatment Protocols
What’s New at MuReva Phototherapy?
MuReva Phototherapy presents data from pilot study of Head and Neck Cancer Patients Treated Daily with an Intraoral Photobiomodulation (PBM) Device during the ASTRO 2023 Annual Meeting
MuReva Phototherapy presented data from a pilot prospective study of the company's Intraoral Photobiomodulation (PBM) Device during the the American Society for Radiation Oncology's (ASTRO) 65th Annual Meeting held from October 1-4, 2023 in San Diego, California. The...
MuReva Phototherapy presents data from pilot study of company’s photobiomodulation device during 2023 MASCC Annual Meeting
MuReva Phototherapy presented data from a pilot trial incorporating the us a the company's LED=based intraoral Photobiomodulation (PBM) device for daily use in head and neck cancer patients undergoing radiation therapy during the 2023 Annual Meeting of the...
As a result of being selected as a 2022 "Cool Company" by Connect, a San Diego-based organization that helps promote top technology and life sciences startups for funding, MuReva Phototherapy will be presenting at the Five·Ten·Thirty program which is a part of the...
MuReva Phototherapy announced today that they have been selected as one of the 2022 "Cool Companies" by Connect, a San Diego-based organization that helps promote top technology and life sciences startups for funding. Cool Companies is an annual Connect program...